



Section 5 – 510(k) Summary

As Required By 21 CFR 807.92

Date of Summary Preparation		May 22, 2014			
Submitter and Owner's Name and Address		Halt Medical, Inc.			
	,	131 Sand Creek Road, Suite B			
		Brentwood, CA 94513			
		Main: (925) 634-7943			
		Fax: (925) 634-7841			
Contact Person		Clarisa A. Tate			
		VP of RA & QA, Halt Medical, Inc.			
		Office: (925) 271-0626			
		e-mail: ctate@haltmedical.com			
Trade Name		Acessa Guidance System			
Common Name		Acessa Guidance System or electromagnetic tracking			
		system			
Classification Name		Unipolar endoscopic coagulator cutter and accessories			
Classification		Class II			
Product Code		HFG, OEW, IYO			
Classification Panel		Obstetrics and Gynecology			
Classification Regulation		21 CFR §884.4160			
Legally Marketed De	vice to which	AIM System (K121479)			
substantial equivaler	nce is claimed				
Intended Use	The Acessa Guidance System is indicated for enhancing the ultrasonic image of the Acessa Handpiece and for predicting its future path on a computer monitor screen which also shows the image of a B-scan (or similar display) of a medical ultrasound imaging system. The device is intended as an optional accessory for use during the Acessa System procedure.				
Device		ystem consists of the following components:			
Description	 Guidance Contro and software use cable. Guidance Ultrase disposable sleev guidance sensor Guidance Field Generator) magnetic guidan Transducer Sleev Guidance Handp Handpiece to the Power Cord (Mo 	oller (Model Number 5100): Contains the tracking systemed to run the system, with attached 4.5m Field Generator ound Transducer Sleeve (Model Number 5500): A e that houses the ultrasound transducer, the magnetic and guidance display control buttons. Generator (Model Number 5200): The TTFG (Table Top generates a magnetic field that is picked up by the ace sensors in the Handpiece and the Ultrasound			



- The Acessa Guidance System must be used with laparoscopic ultrasound.
 Laparoscopic ultrasound equipment is not included with the Acessa
 Guidance System.
- The Acessa Guidance System may only be used with the Acessa System, a radiofrequency ablation device.

The Acessa Guidance System uses electromagnetic tracking technology to track the positions of the Guidance Ultrasound Transducer Sleeve and the Guidance Handpiece shaft and draws virtual representations of them in their spatial relationship, so that a physician can predict the Guidance Handpiece shaft's future path in relation to the features in the ultrasound slice. The Acessa Guidance System is considered an optional accessory to procedures where ultrasound is currently used for visualization, such as the Acessa System procedure.

Technological Characteristics Compared to Predicate Devices

The design features and principal modes of operation of the Acessa Guidance System is the equivalent to the commercially available AIM System. Both products are configured the same and the software is made by the predicate device's company which they based on their cleared device.

Application of electromagnetic tracking technology with both devices within a surgical procedure is completed in the same manner. Substantial equivalence is established with respect to the same indication for use, principal design, software used, performance, and safety requirements.

Performance Testing

The Acessa Guidance System was subjected to electrical and safety testing according to risks assessments performed based on the differences with the predicate device. EMC and safety testing were completed on the device as required by ANSI/AAMI ES 60601-1:2005 with A2:2010 3rd edition Medical Device Equipment Part 1 General Requirements for Safety, EN/IEC 60601-1-2:2007 3rd edition Medical Electrical Equipment General Requirements for Basic Safety and Essential Performance Collateral Standard Electromagnetic Compatibility Requirements and Tests, IEC 60601-1-4:2000 1st edition Medical Electrical Equipment Par 1-4: General Requirements for Safety – Collateral Standard: Programmable Electrical Medical Systems. The device passed all testing.

A series of biocompatibility testing also demonstrated that the device with its additional materials are safe, suitable, and appropriate for their intended use and in compliance with ISO 10993-1:2009 4th edition Biological Evaluation of Medical Devices Part 1 Evaluation and Testing within a Risk Management Process, ISO 10993-5:2009 3rd edition Biological Evaluation of Medical Devices Tests for In Vitro Cytotoxicity, ISO 10993-10:2010 2nd edition Biological Evaluation of Medical Devices Tests for Irritation and Delayed-Type Hypersensitivity, and ISO 10993-11:2006 2nd edition Biological Evaluation of Medical Devices Tests for Systemic Toxicity.

The Acessa Guidance System was also subjected to Guidance Sleeve end cap tensile testing as well as system worse-case accuracy comparison testing in a

Halt Medical, Inc.' Traditional 510(k) Premarket Submission Acessa Guidance System



	simulated clinical environment. The device met all criteria.
	Software validations were also conducted, which was conducted by the same manufacturer of the predicate device.
Conclusion	The Acessa Guidance System is substantially equivalent to the legally marketed medical device as demonstrated by the technological characteristics comparison and performance testing completed for this device.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

May 27, 2014

Halt Medical, Inc.
Clarisa A. Tate
Vice President of Regulatory Affairs & Quality Assurance
131 Sand Creek Road, Suite B
Brentwood, CA 94513-2040

Re: K132744

Trade/Device Name: Acessa Guidance System

Regulation Number: 21 CFR§ 884.4160

Regulation Name: Unipolar endoscopic coagulator cutter and accessories

Regulatory Class: II Product Code: HFG Dated: April 25, 2014 Received: April 28, 2014

Dear Clarisa A. Tate,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,



Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known):

Device Name: Acessa Guidance System							
Indications for Use: The Acessa Guidance System is indicated for enhancing the ultrasonic image of the Acessa Handpiece and for predicting its future path on a computer monitor screen which also shows the image of a B-scan (or similar display) of a medical ultrasound imaging system. The device is intended as an optional accessory for use during the Acessa System procedure.							
		·					
Prescription Use (Part 21 CFR 801	•	AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)				
(PLEASE DO NOT V	VRITE BELOW THIS I	LINE – CONTINU	E ON ANOTHER PAGE IF NEEDED)				

Concurrence of CDRH, Office of Device Evaluation (ODE)

Benjamin R. Fisher -S 2014.05.27 16:03:04 -04'00'